<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296931</url>
  </required_header>
  <id_info>
    <org_study_id>14-081F</org_study_id>
    <nct_id>NCT02296931</nct_id>
  </id_info>
  <brief_title>Assessment of a Syringe Pump to Pre-eclamptic Women in a Low-resource Hospital</brief_title>
  <official_title>Laboratory and Pilot Clinical Assessment of the Accuracy, Usability, and Function of a Low-cost, Low-power Syringe Pump in Administering Magnesium Sulfate to Pre-eclamptic Women in a Low-resource Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Marsh Rice University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Malawi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>William Marsh Rice University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-eclampsia and eclampsia cause 50,000 deaths annually. While MgSO4 is a widely accepted&#xD;
      and relatively inexpensive treatment for these conditions, barriers to delivery via IV&#xD;
      injection in low-resource settings pose a large obstacle to reductions in mortality. AutoSyP&#xD;
      is a low-cost, low-powered automatic syringe pump that could overcome this barrier to the&#xD;
      delivery of MgSO4. We propose to conduct a pilot clinical evaluation of its ability to&#xD;
      deliver MgSO4 to women with pre-eclampsia or eclampsia in Malawi.&#xD;
&#xD;
      AutoSyP will be the subject of a 2 phase pilot clinical community trial in Malawi. Prior to&#xD;
      the start of the study, all nurses will receive a 4-hour training on AutoSyP use to ensure&#xD;
      proper procedures are followed. Phase 1 will be an initial validation of the clinical&#xD;
      performance of the device delivering only standard IV saline to 10 stable women. The study&#xD;
      will continue to Phase 2 where, the device will deliver MgSO4 to up to 40 women presenting&#xD;
      with symptoms of pre-eclampsia.&#xD;
&#xD;
        1. Prior to the start of the study, all nurses will receive a 4-hour training on AutoSyP&#xD;
           use.&#xD;
&#xD;
        2. Eligible and willing participants will provide informed consent. Then, baseline&#xD;
           demographic and relevant medical history information will be collected.&#xD;
&#xD;
        3. In Phase 1, subjects will receive IV saline fluids by the Nurse. In Phase 2, the Nurse&#xD;
           will provide loading dose of MgSO4 with the AutoSyP and research staff will monitor and&#xD;
           record device performance and treatment specifications.&#xD;
&#xD;
        4. Subsequent maintenance doses of saline or MgSO4 will be administered and observations&#xD;
           monitored and recorded for up to 24 hours as clinically indicated.&#xD;
&#xD;
      Others may benefit from this study in the future as AutoSyP is a new delivery system is&#xD;
      needed to break down the barriers to IV delivery of MgSO4 in low-resource settings. The&#xD;
      results of this study will be made available to the Ministry of Health, NHSRC, COMREC, the&#xD;
      College of Medicine Library, the Department of Paediatrics, and other partners working in&#xD;
      neonatal and child health. Findings will be published in academic journals and conference&#xD;
      proceedings in an effort to disseminate results to potential end-users. The research findings&#xD;
      of this study will be critical in the evaluation of future interventions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will recruit patients from two clinical sites (Kamuzu Central Hospital in Lilongwe,&#xD;
      Malawi and Queen Elizabeth Central Hospital in Blantyre, Malawi) through their healthcare&#xD;
      providers. Malawi represents an ideal location to conduct such a study as there are&#xD;
      approximately 17,000 cases of pre-eclampsia annually. The study will include up to 40 women&#xD;
      presenting with symptoms of pre-eclampsia.&#xD;
&#xD;
      The study will include pregnant women diagnosed with pre-eclampsia deemed to benefit from&#xD;
      treatment with MgSO4 by healthcare providers at our participating clinical sites. Women who&#xD;
      are eclamptic or seizing at the time of enrollment or have received MgSO4 therapy within the&#xD;
      preceding 24 hours prior to study enrollment will be ineligible.&#xD;
&#xD;
      We will conduct an interventional study of the use of AutoSyP to deliver MgSO4 in two&#xD;
      clinical setting in Malawi; Queen Elizabeth Central Hospital and Kamuzu Central Hospital. The&#xD;
      study will be open and non-blinded due to ethical considerations that would arise from the&#xD;
      denial of the experimental treatment to participants when there is no alternative form of IV&#xD;
      MgSO4 delivery available.&#xD;
&#xD;
      All eligible and consenting women will be assigned to have treatment with AutoSyP if an&#xD;
      AutoSyP device is available. If an AutoSyP device is not available, the participant will&#xD;
      receive treatment for pre-eclampsia according to the standard of care at the hospital.&#xD;
&#xD;
      Pilot Clinical Evaluation Training&#xD;
&#xD;
        1. Prior to the start of the study, all nurses will receive a 4-hour training on AutoSyP&#xD;
           use.&#xD;
&#xD;
        2. All trained nurses will receive an identification number that will be used for&#xD;
           recordkeeping throughout the study.&#xD;
&#xD;
      Selection of Participants&#xD;
&#xD;
        1. Participants will be identified using the eligibility criteria stipulated above.&#xD;
&#xD;
        2. Willing participants will provide informed consent to participate in the study.&#xD;
&#xD;
        3. A participant identification number will be assigned. This number will be used for&#xD;
           identification purposes throughout the study.&#xD;
&#xD;
        4. Baseline demographic and relevant medical history information will be collected.&#xD;
&#xD;
      Treatment&#xD;
&#xD;
        1. Nurse will provide loading dose with the AutoSyP. A trained Rice research assistant will&#xD;
           observe all procedures and will correct any errors made by the nurse or answer any&#xD;
           questions from the nurse.&#xD;
&#xD;
        2. The Rice research assistant will monitor the performance of the AutoSyP, watching for&#xD;
           any device malfunctions and notify the nurse if any are observed. The Rice research&#xD;
           assistant will help the nurse to correct the device malfunction and treatment will&#xD;
           continue; otherwise, an alternative AutoSyP device will be used to continue treatment.&#xD;
           The research assistant will also use a timer to record the duration of the dose.&#xD;
&#xD;
        3. The research assistant will record the following information:&#xD;
&#xD;
             1. MgSO4 concentration used and syringe size&#xD;
&#xD;
             2. Duration of administration&#xD;
&#xD;
             3. Initial device set-up errors/questions by the nurse (e.g., user cannot operate&#xD;
                device, user must ask for help)&#xD;
&#xD;
             4. Observed malfunctions of AutoSyP&#xD;
&#xD;
             5. Identification number of the nurse operating AutoSyP&#xD;
&#xD;
             6. Identification number of the device&#xD;
&#xD;
        4. Nurse provides maintenance doses with AutoSyP after the loading dose is complete.&#xD;
&#xD;
        5. Rice research assistant repeats tasks 2-3 with reference to the maintenance dose.&#xD;
&#xD;
        6. Nurse continues to provide maintenance doses for up to 24 hours as necessary.&#xD;
&#xD;
        7. Rice research assistant repeats tasks 2-3 for each maintenance dose.&#xD;
&#xD;
        8. Treatment will be discontinued when clinically indicted.&#xD;
&#xD;
        9. Rice research assistant records the total number of doses provided and the clinical&#xD;
           outcome of the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">October 3, 2017</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Error in the Total Volume Dispensed and Flow Rate</measure>
    <time_frame>1 day visit</time_frame>
    <description>This is the error value for the volume dispensed by the AutoSyp device relative to the volume intended to be dispensed. Preeclamptic subjects received an initial loading dose followed by a maintenance dose. The loading dose had a flow rate of 60 mL/hr and delivered 20 mL in a single 20 mL syringe. The maintenance dose was 5 mL/hr and dispensed 120 mL total through two 60 mL syringes. The healthy subjects experienced variable flow rates and dispensed volumes, so they do not have the same variables as the pre-eclamptic pregnant women in the outcome data tables below. Because of these differences in dosing the two arms of the study, healthy women and preeclamptic women have different outcome measure data.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pre-eclampsia</condition>
  <arm_group>
    <arm_group_label>Healthy Adults</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-eclamptic pregnant women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Standard IV Saline Fluids</description>
    <arm_group_label>Healthy Adults</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)</description>
    <arm_group_label>Pre-eclamptic pregnant women</arm_group_label>
    <other_name>MgSO4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 1: Healthy Volunteers&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
          -  Agree to comply with study procedures&#xD;
&#xD;
          -  Deemed medically stable by their healthcare provider, including normal range blood&#xD;
             pressure.&#xD;
&#xD;
          -  Have been clinically identified to be able to receive standard IV saline fluid&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with a history of heart disease of cardiac complications.&#xD;
&#xD;
          -  Women with a history of complications with an IV.&#xD;
&#xD;
        Phase 2: Pre-eclamptic Women&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
          -  Agree to comply with study procedures&#xD;
&#xD;
          -  Have systolic blood pressure P140mm Hg or a diastolic blood pressure P100mm Hg and&#xD;
             proteinuria P1+.&#xD;
&#xD;
          -  Be pregnant or are &lt;24 hours postpartum.&#xD;
&#xD;
          -  Diagnosed with pre-eclampsia and deemed to benefit from treatment with MGSO4 by&#xD;
             healthcare providers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have systolic blood pressure P140mm Hg or a diastolic blood pressure P100mm Hg and&#xD;
             proteinuria P1+.&#xD;
&#xD;
          -  Be pregnant or are &lt;24 hours postpartum.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca R Kortum, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Marsh Rice University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Central Hospital</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <reference>
    <citation>Duley L, GÃ¼lmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010 Nov 10;(11):CD000025. doi: 10.1002/14651858.CD000025.pub2. Review.</citation>
    <PMID>21069663</PMID>
  </reference>
  <reference>
    <citation>Connor SB, Quill TJ, Jacobs JR. Accuracy of drug infusion pumps under computer control. IEEE Trans Biomed Eng. 1992 Sep;39(9):980-2.</citation>
    <PMID>1473827</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <results_first_submitted>June 24, 2016</results_first_submitted>
  <results_first_submitted_qc>August 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2016</results_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William Marsh Rice University</investigator_affiliation>
    <investigator_full_name>Rebecca Richards-Kortum</investigator_full_name>
    <investigator_title>Stanley C. Moore Professor, Bioengineering</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Adults</title>
          <description>Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.&#xD;
Saline: Standard IV Saline Fluids</description>
        </group>
        <group group_id="P2">
          <title>Pre-eclamptic Pregnant Women</title>
          <description>In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.&#xD;
Magnesium Sulfate: The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Adults</title>
          <description>Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.&#xD;
Saline: Standard IV Saline Fluids</description>
        </group>
        <group group_id="B2">
          <title>Pre-eclamptic Pregnant Women</title>
          <description>In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.&#xD;
Magnesium Sulfate: The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="23" upper_limit="50"/>
                    <measurement group_id="B2" value="26" lower_limit="19" upper_limit="37"/>
                    <measurement group_id="B3" value="27" lower_limit="19" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Malawi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Error in the Total Volume Dispensed and Flow Rate</title>
        <description>This is the error value for the volume dispensed by the AutoSyp device relative to the volume intended to be dispensed. Preeclamptic subjects received an initial loading dose followed by a maintenance dose. The loading dose had a flow rate of 60 mL/hr and delivered 20 mL in a single 20 mL syringe. The maintenance dose was 5 mL/hr and dispensed 120 mL total through two 60 mL syringes. The healthy subjects experienced variable flow rates and dispensed volumes, so they do not have the same variables as the pre-eclamptic pregnant women in the outcome data tables below. Because of these differences in dosing the two arms of the study, healthy women and preeclamptic women have different outcome measure data.</description>
        <time_frame>1 day visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Adults</title>
            <description>Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.&#xD;
Saline: Standard IV Saline Fluids</description>
          </group>
          <group group_id="O2">
            <title>Pre-eclamptic Pregnant Women</title>
            <description>In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.&#xD;
Magnesium Sulfate: The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)</description>
          </group>
        </group_list>
        <measure>
          <title>Error in the Total Volume Dispensed and Flow Rate</title>
          <description>This is the error value for the volume dispensed by the AutoSyp device relative to the volume intended to be dispensed. Preeclamptic subjects received an initial loading dose followed by a maintenance dose. The loading dose had a flow rate of 60 mL/hr and delivered 20 mL in a single 20 mL syringe. The maintenance dose was 5 mL/hr and dispensed 120 mL total through two 60 mL syringes. The healthy subjects experienced variable flow rates and dispensed volumes, so they do not have the same variables as the pre-eclamptic pregnant women in the outcome data tables below. Because of these differences in dosing the two arms of the study, healthy women and preeclamptic women have different outcome measure data.</description>
          <units>percentage of error</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Volume Dispensed-Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Healthy adults experienced variable dispensed volumes in contrast to the fixed volumes dispensed for the pre-eclamptic arm. This category is only for the error experienced by the pre-eclamptic arm regarding their fixed loading dose volume of 20mL</measurement>
                    <measurement group_id="O2" value="-1.48" lower_limit="-2.58" upper_limit="-0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flow Rate-Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Healthy adults experienced variable flow rates in contrast to the fixed flow rates of the pre-eclamptic arm. This category is only for the error experienced by the pre-eclamptic arm regarding their loading dose flow rate of 60mL/hr.</measurement>
                    <measurement group_id="O2" value="-1.75" lower_limit="-2.53" upper_limit="-1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Volume Dispensed-Maintenance Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Healthy adults had variable dispensed volumes in contrast to the fixed volumes dispensed for the pre-eclamptic arm. This category is for the error experienced by the pre-eclamptic arm regarding their maintenance dose dispensed volume of 120mL .</measurement>
                    <measurement group_id="O2" value="-1.13" lower_limit="-2.28" upper_limit="-0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flow Rate-Maintenance Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Healthy adults experienced variable flow rates in contrast to the fixed flow rates for the pre-eclamptic arm. This category is only for the error experienced by the pre-eclamptic arm regarding their maintenance dose flow rate of 5mL/hr.</measurement>
                    <measurement group_id="O2" value="-1.11" lower_limit="-2.09" upper_limit="-0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flow Rate-Variable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" lower_limit="-2.90" upper_limit="4.95"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Healthy adult women experienced variable flow rates in contrast to the fixed flow rates for the pre-eclamptic arm. This category is only for the variable flow rate error experienced by the health adult arm.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Volume Dispensed-Variable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" lower_limit="-3.65" upper_limit="2.60"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Healthy adult women experienced variable dispensed volumes in contrast to the fixed volumes dispensed for the pre-eclamptic arm. This category is only for the error in total volume dispensed experienced by the healthy adult arm.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Healthy Adults</title>
          <description>Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.&#xD;
Saline: Standard IV Saline Fluids</description>
        </group>
        <group group_id="E2">
          <title>Pre-eclamptic Pregnant Women</title>
          <description>In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.&#xD;
Magnesium Sulfate: The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rebecca Richards-Kortum</name_or_title>
      <organization>Rice 360: Institute for Global Health</organization>
      <phone>713-348-3823</phone>
      <email>rkortum@rice.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

